Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acceleron’s GDF Therapies: Just Different Enough?

This article was originally published in The Pink Sheet Daily

Executive Summary

EPO-like, Avastin-like portfolio is designed for “enormous” indications, but piggy-back possibilities are too early to forecast.

You may also be interested in...



Affymax Swings $42 Million Financing To Push Hematide

Private/public infusion will see synthetic ESA through trials and approval.

Amgen Submits Denosumab BLA Ahead Of Expectations

Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.

The Future Of ESAs – Is It All CKD Now?

Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel